IFNG and graft versus host disease: In an analysis of a MSC-based off-the-shelf cell product, intravenous infusions of CymerusTM MSCs (Cynata Therapeutics) ameliorated disease and prolonged survival in a humanized GVHD mouse model after treating cells with IFN-γ (57).